These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

681 related items for PubMed ID: 9876058

  • 1. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
    Ferrari S, Mercuri M, Rosito P, Mancini A, Barbieri E, Longhi A, Rimondini S, Cesari M, Ruggieri P, Di Liddo M, Bacci G.
    J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
    [Abstract] [Full Text] [Related]

  • 2. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
    Bacci G, Picci P, Ferrari S, Mercuri M, Brach del Prever A, Rosito P, Barbieri E, Tienghi A, Forni C.
    Cancer; 1998 Mar 15; 82(6):1174-83. PubMed ID: 9506366
    [Abstract] [Full Text] [Related]

  • 3. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
    Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Miser JS.
    N Engl J Med; 2003 Feb 20; 348(8):694-701. PubMed ID: 12594313
    [Abstract] [Full Text] [Related]

  • 4. Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
    Tural D, Molinas Mandel N, Dervisoglu S, Oner Dincbas F, Koca S, Colpan Oksuz D, Kantarci F, Turna H, Selcukbiricik F, Hiz M.
    Jpn J Clin Oncol; 2012 May 20; 42(5):420-6. PubMed ID: 22416252
    [Abstract] [Full Text] [Related]

  • 5. No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies.
    Bacci G, Picci P, Ruggieri P, Ferrari S, Mercuri M, Fabbri N, Rosito P, Barbieri E, Ferraro A, Casadei R.
    J Chemother; 1993 Aug 20; 5(4):247-57. PubMed ID: 8229153
    [Abstract] [Full Text] [Related]

  • 6. [Neoadjuvant treatment of Ewing's sarcoma: results obtained in 122 patients treated with a 6-drug chemotherapeutic protocol (vincristine, adriamycin, cyclophosphamide, dactinomycin, ifosfamide and etoposide)].
    Bacci G, Ferrari S, Rosito P, Barbieri E, Mercuri M, Brach del Prever A, Iantorno D, Forni C, Campanacci M.
    Minerva Pediatr; 1995 Nov 20; 47(11):457-69. PubMed ID: 8684341
    [Abstract] [Full Text] [Related]

  • 7. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.
    Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, Amann G, Dockhorn-Dworniczak B, Harms D, Müller-Weihrich S, Welte K, Kornhuber B, Janka-Schaub G, Göbel U, Treuner J, Voûte PA, Zoubek A, Gadner H, Jürgens H.
    J Clin Oncol; 2001 Mar 15; 19(6):1818-29. PubMed ID: 11251014
    [Abstract] [Full Text] [Related]

  • 8. Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli.
    Bacci G, Ferrari S, Bertoni F, Donati D, Bacchini P, Longhi A, Brach Del Prever A, Forni C, Rimondini S.
    J Clin Oncol; 2000 Feb 15; 18(4):885-92. PubMed ID: 10673532
    [Abstract] [Full Text] [Related]

  • 9. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
    Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Grier HE.
    J Clin Oncol; 2004 Jul 15; 22(14):2873-6. PubMed ID: 15254055
    [Abstract] [Full Text] [Related]

  • 10. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, Schuck A, Winkelmann W, Köhler G, Poremba C, Zoubek A, Ladenstein R, van den Berg H, Hunold A, Cassoni A, Spooner D, Grimer R, Whelan J, McTiernan A, Jürgens H, European Intergroup Cooperative Ewing's Sarcoma Study-92.
    J Clin Oncol; 2008 Sep 20; 26(27):4385-93. PubMed ID: 18802150
    [Abstract] [Full Text] [Related]

  • 11. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial.
    Dunst J, Jürgens H, Sauer R, Pape H, Paulussen M, Winkelmann W, Rübe C.
    Int J Radiat Oncol Biol Phys; 1995 Jul 15; 32(4):919-30. PubMed ID: 7607966
    [Abstract] [Full Text] [Related]

  • 12. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
    Kushner BH, Meyers PA.
    J Clin Oncol; 2001 Feb 01; 19(3):870-80. PubMed ID: 11157041
    [Abstract] [Full Text] [Related]

  • 13. Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma.
    Bacci G, Picci P, Mercuri M, Ferrari S, Longhi A, Cesari M, Rosito P, Mancini AF, Barbieri E, Baldini N.
    Acta Oncol; 1998 Feb 01; 37(7-8):671-6. PubMed ID: 10050985
    [Abstract] [Full Text] [Related]

  • 14. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors.
    Wexler LH, DeLaney TF, Tsokos M, Avila N, Steinberg SM, Weaver-McClure L, Jacobson J, Jarosinski P, Hijazi YM, Balis FM, Horowitz ME.
    Cancer; 1996 Aug 15; 78(4):901-11. PubMed ID: 8756388
    [Abstract] [Full Text] [Related]

  • 15. Ewing's sarcoma: evaluation of chemotherapy in 17 cases.
    Ozaki T, Inoue H, Sugihara S, Hamada M, Nakagawa Y, Taguchi K.
    Hiroshima J Med Sci; 1993 Jun 15; 42(2):89-96. PubMed ID: 8253602
    [Abstract] [Full Text] [Related]

  • 16. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.
    Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P, Forni C, Manfrini M, Donati D, Picci P.
    J Clin Oncol; 2000 Jan 15; 18(1):4-11. PubMed ID: 10623687
    [Abstract] [Full Text] [Related]

  • 17. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study.
    Craft A, Cotterill S, Malcolm A, Spooner D, Grimer R, Souhami R, Imeson J, Lewis I.
    J Clin Oncol; 1998 Nov 15; 16(11):3628-33. PubMed ID: 9817284
    [Abstract] [Full Text] [Related]

  • 18. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone.
    Meyer WH, Kun L, Marina N, Roberson P, Parham D, Rao B, Fletcher B, Pratt CB.
    J Clin Oncol; 1992 Nov 15; 10(11):1737-42. PubMed ID: 1403056
    [Abstract] [Full Text] [Related]

  • 19. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
    Jürgens H, Exner U, Kühl J, Ritter J, Treuner J, Weinel P, Winkler K, Göbel U.
    Cancer Chemother Pharmacol; 1989 Nov 15; 24 Suppl 1():S40-4. PubMed ID: 2503258
    [Abstract] [Full Text] [Related]

  • 20. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
    Dunst J, Ahrens S, Paulussen M, Rübe C, Winkelmann W, Zoubek A, Harms D, Jürgens H.
    Int J Radiat Oncol Biol Phys; 1998 Sep 01; 42(2):379-84. PubMed ID: 9788419
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.